Citius Oncology, Inc. (CTOR) vs Humacyte, Inc. (HUMA)
A side-by-side comparison of Citius Oncology, Inc. and Humacyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTOR
Citius Oncology, Inc.
$0.90HealthcareDelayed quote: Oct 6, 2026, 11:54 AM EDT
HUMA
Humacyte, Inc.
$0.50HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — CTOR vs HUMA
growth of $100 · dividends reinvested · last 2yCTOR -92.4% (-72.4%/yr)HUMA -94.0% (-75.4%/yr)CTOR compounded faster over this window
CTOR HUMA
CTOR vs HUMA: by the numbers
- •HUMA is the larger company ($84M vs $83M market cap).
- •Both run net losses; CTOR's is the smaller (-648.32% vs -4560.82% net margin).
Metrics side by side
Valuation
| Metric | CTOR | HUMA |
|---|---|---|
| Forward P/E | 8.98 | N/A |
| P/S ratio | 11.75 | 39.69 |
| P/B ratio | 2.07 | 2.69 |
Profitability
| Metric | CTOR | HUMA |
|---|---|---|
| Gross margin | 0.00% | -736.46% |
| Operating margin | 0.00% | -5271.69% |
| Net margin | -648.32% | -4560.82% |
| ROE | -114.06% | -309.44% |
| ROIC | -88.72% | -90.27% |
Growth (annualized)
| Metric | CTOR | HUMA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 2.41% |
| Total return CAGR (5Y) | N/A | -45.73% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.